ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Comparison of Transfer Learning and Conventional Machine Learning Applied to Structural Brain MRI for the Early Diagnosis and Prognosis of Alzheimer's Disease

Nanni, Loris; Interlenghi, Matteo; Brahnam, Sheryl; Salvatore, Christian*; Papa, Sergio; Nemni, Raffaello; Castiglioni, Isabella
Frontiers in Neurology2020-11-5DOI: 10.3389/fneur.2020.576194
39被引8阅读
引用收藏
分享

摘要

Alzheimer's Disease (AD) is the most common neurodegenerative disease, with 10% prevalence in the elder population. Conventional Machine Learning (ML) was proven effective in supporting the diagnosis of AD, while very few studies investigated the performance of deep learning and transfer learning in this complex task. In this paper, we evaluated the potential of ensemble transfer-learning techniques, pretrained on generic images and then transferred to structural brain MRI, for the early diagnosis and prognosis of AD, with respect to a fusion of conventional-ML approaches based on Support Vector Machine directly applied to structural brain MRI. Specifically, more than 600 subjects were obtained from the ADNI repository, including AD, Mild Cognitive Impaired converting to AD (MCIc), Mild Cognitive Impaired not converting to AD (MCInc), and cognitively-normal (CN) subjects. We used T1-weighted cerebral-MRI studies to train: (1) an ensemble of five transfer-learning architectures pretrained on generic images; (2) a 3D Convolutional Neutral Network (CNN) trained from scratch on MRI volumes; and (3) a fusion of two conventional-ML classifiers derived from different feature extraction/selection techniques coupled to SVM. The AD-vs-CN, MCIc-vs-CN, MCIc-vs-MCInc comparisons were investigated. The ensemble transfer-learning approach was able to effectively discriminate AD from CN with 90.2% AUC, MCIc from CN with 83.2% AUC, and MCIc from MCInc with 70.6% AUC, showing comparable or slightly lower results with the fusion of conventional-ML systems (AD from CN with 93.1% AUC, MCIc from CN with 89.6% AUC, and MCIc from MCInc with AUC in the range of 69.1-73.3%). The deep-learning network trained from scratch obtained lower performance than either the fusion of conventional-ML systems and the ensemble transfer-learning, due to the limited sample of images used for training. These results open new prospective on the use of transfer learning combined with neuroimages for the automatic early diagnosis and prognosis of AD, even if pretrained on generic images.

学科与关键词

关键词
artificial intelligencedeep learningmagnetic resonance imagingAlzheimer' s diseasemild cognitive impairmenttransfer learningCNN&#8211convolutional neural networks
相关
加载中…
  • Early diagnosis of Alzheimer's disease based on deep learning: A systematic review
    Fathi, Sina; Ahmadi, Maryam*; Dehnad, AfsanehComputers in Biology and Medicine, 2022, 146: 105634.被引 37
  • DeepCurvMRI: Deep Convolutional Curvelet Transform-Based MRI Approach for Early Detection of Alzheimer's Disease
    Chabib, Chahd M.; Hadjileontiadis, Leontios J.; Shehhi, Aamna Al*IEEE Access, 2023, 11: 44650-44659.被引 6
  • Real-world prediction of preclinical Alzheimer's disease with a deep generative model
    Hwang, Uiwon; Kim, Sung-Woo; Jung, Dahuin; Kim, SeungWook; Lee, Hyejoo; Seo, Sang Won; Seong, Joon-Kyung*; Yoon, Sungroh*Artificial Intelligence in Medicine, 2023, 144: 102654.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Neurology
发表日期
2020-11-05
卷期
第 11 卷
页码
576194
DOI
10.3389/fneur.2020.576194
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
3区
成果收录
SCIE
资助标注
Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]; DOD ADNI (Department of Defense) [W81XWH-12-2-0012]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd.; company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research and Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; Transition Therapeutics; Canadian Institutes of Health Research

作者

  • N

    Nanni, Loris (第一作者)

  • I

    Interlenghi, Matteo

查看全部 7 位作者收起作者
  • B

    Brahnam, Sheryl

  • S

    Salvatore, Christian (通讯)

  • P

    Papa, Sergio

  • N

    Nemni, Raffaello

  • C

    Castiglioni, Isabella

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417